# x-cardiac

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/x-cardiac

- Industry: Software
- Headquarters: Berlin, Germany
- Website: www.xcardiac.com
- Latest round: Seed (Apr 22, 2021)
- Investors on record: 1

## About

x-cardiac GmbH is a Berlin-based company focused on developing AI solutions that enhance patient care in ICUs, particularly after cardiac surgeries, by predicting critical post-operative complications.Founded in 2020 by Alexander Meyer and Carsten Eickhoff, x-cardiac GmbH operates out of Berlin, Germany. The company specializes in creating technology that aims to improve patient outcomes through predictive analytics. It recently completed its first deal on 22 April 2021, raising funds to support its product offerings.x-cardiac GmbH specializes in developing advanced artificial intelligence (AI) solutions to improve patient care in intensive care units (ICUs), particularly following cardiac surgery. The company’s flagship product, the x-cardiac-platform, utilizes clinically validated algorithms to predict life-threatening complications, including post-operative bleeding and renal injury. This platform ensures 100% interoperability with existing hospital IT systems. Specific plugins include x-c-bleeding™, which addresses post-operative bleeding, and x-c-renal-injury™, focusing on early detection of renal injuries. The primary users of these products are hospitals and healthcare facilities across Europe and North America, where there is a strong demand for enhanced patient monitoring and outcomes.x-cardiac GmbH generates revenue through the sale of its AI-based medical devices and software solutions directly to healthcare institutions. The company's transactions are primarily B2B, involving partnerships with hospitals that integrate its technology. Revenue is structured around licensing fees for the x-cardiac-platform and its plugins, as well as potential subscription models for ongoing support and updates. Although specific pricing details for the x-c-bleeding™ and x-c-renal-injury™ plugins have not been disclosed, these tools are essential for ICU staff in critical care situations.In April 2021, x-cardiac GmbH raised an undisclosed amount in a SEED round from IBB Ventures and individual investors. The company plans to utilize this funding to certify and support the launch of the x-c-bleeding™ plugin, specifically designed to mitigate postoperative bleeding risks. Future strategies include expanding into additional European markets and potentially North America within the next 2 years, enhancing their product offerings to meet the growing demand for AI-driven solutions in healthcare.

## Funding rounds

- Seed, Apr 22, 2021 — IBB Ventures

## Investors

- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Seed